SEATTLE, WA – Immunex Corporation (Nasdaq: IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP) announced today that the U.S. Food and Drug Administration (FDA) has ...

Sofusa is a drug delivery platform technology which delivers biologic therapies through the skin directly into the lymphatic system with potential to improve efficacy and safety and reduce the ...

Amgen and Pfizer Announce Results From the Largest Completed Clinical Trial of a Biologic Therapy in Adults with Moderately Active RA THOUSAND OAKS, Calif. and NEW YORK, Nov. 5, 2011 /PRNewswire/ -- ...

Amgen and Wyeth Pharmaceuticals, a division of Wyeth, today announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein, a marker of inflammation, in ...

Sorrento Therapeutics announced that the first patient has been treated in a phase 1b proof-of-concept, open-label study to assess the safety and pilot efficacy of Enbrel administered by the Sofusa ...

Oct. 14, 2004 — The U.S. Food and Drug Administration (FDA) has approved caspofungin acetate for the empiric treatment of presumed fungal infections in the setting of febrile neutropenia, etanercept ...

Doctors prescribe Enbrel for arthritis, psoriasis, and other conditions. The medication can cause side effects that are mild and some serious ones. Serious side effects of Enbrel include neurologic ...

European regulators have expanded the license for Pfizer's Enbrel to include five subtypes of Juvenile Idiopathic Arthritis (JIA), and have also approved a more convenient once-weekly dosing regimen.

May 23, 2005 — The European Commission has approved a 50-mg/mL formulation of etanercept injection for the treatment of rheumatoid arthritis, and the U.K.'s Medicine and Healthcare Products Regulatory ...

THOUSAND OAKS, Calif. and NEW YORK, Nov. 5, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results of the second and final period of the PRESERVE trial. PRESERVE ...